Characterisation of the HLA-DRB1 * 07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and / or taxanes

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes The Pharmacogenomics Journal advance online publication, August 8 2017. doi:10.1038/tpj.2017.39 Authors: C F Spraggs, L R Parham, L P Briley, L Warren, L S Williams, D J Fraser, Z Jiang, Z Aziz, S Ahmed, G Demetriou, A Mehta, N Jackson, J Byrne, M Andersson, M Toi, L Harris, J Gralow, J A Zujewski, R Crescenzo, A Armour, E Perez & M Piccart
Source: The Pharmacogenomics Journal - Category: Drugs & Pharmacology Authors: Source Type: research